# Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

> **NCT00520598** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 511 (actual)

## Conditions studied

- Cervical Cancer
- Vulvar Cancer
- Vaginal Cancer
- Genital Warts
- Human Papillomavirus Infection

## Interventions

- **BIOLOGICAL:** Comparator: V505 formulation 1
- **DRUG:** Comparator: V505 formulation 2
- **DRUG:** Comparator: V505 formulation 2
- **BIOLOGICAL:** Comparator: V505 formulation 3
- **BIOLOGICAL:** Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant
- **BIOLOGICAL:** Comparator: Placebo (unspecified)

## Key facts

- **NCT ID:** NCT00520598
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 511 (ACTUAL)
- **Last updated:** 2015-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00520598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00520598, "Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00520598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*